Literature DB >> 1868734

Oral contraceptives and cervical neoplasia.

L A Brinton1.   

Abstract

Although initial studies examining the relationship of oral contraceptives to risk of cervical neoplasia were reassuring, more recent studies provide some evidence of a positive relationship, particularly for long-term usage. Results, however, are difficult to interpret, because of a variety of methodologic complexities, including potential sources of confounding and bias. Sexual behavior and Pap smear screening have been identified as important confounders, but in several well-controlled studies residual excess risks of nearly 2-fold persist for users of 5 or more years. A possible promotional effect of oral contraceptives is suggested by higher risks associated with recent usage. There also is some suggestion of a stronger effect for adenocarcinomas than for squamous cell tumors. A relationship is biologically possible, given findings of hormone receptors in cervical tissue and the fact that oral contraceptives have been found to induce cervical hyperplasia. In addition, oral contraceptives may induce proliferation of the human papillomaviruses, the leading suspect agent for cervical cancer. Although a number of lines of evidence support a relationship of oral contraceptives to cervical cancer risk, firm conclusions await the results of additional studies that specifically address some of the methodologic shortcomings of previous investigations. In particular, additional follow-up studies are needed to define the effect of oral contraceptives on the natural history of cervical lesions.

Entities:  

Keywords:  Biology; Cancer; Cervical Cancer--etiology; Cervical Effects; Cervix; Contraception; Contraceptive Methods--side effects; Diseases; Family Planning; Genitalia; Genitalia, Female; Literature Review; Neoplasms; Oral Contraceptives--side effects; Physiology; Risk Factors; Urogenital System; Uterus

Mesh:

Substances:

Year:  1991        PMID: 1868734     DOI: 10.1016/0010-7824(91)90005-z

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  8 in total

1.  The upstream regulatory region of human papillomavirus type 31 is insensitive to glucocorticoid induction.

Authors:  Jennifer L Bromberg-White; Craig Meyers
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 2.  Hormonal contraception in adolescents: special considerations.

Authors:  Rollyn M Ornstein; Martin M Fisher
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  Cyclin D1 (G870A) polymorphism and risk of cervix cancer: a case control study in north Indian population.

Authors:  Kaur Satinder; Sobti Ranbir Chander; Kaur Pushpinder; Gupta Indu; Jain Veena
Journal:  Mol Cell Biochem       Date:  2008-06-12       Impact factor: 3.396

Review 4.  Contraceptive steroids and the mammary gland: is there a hazard?--Insights from animal studies.

Authors:  G R Rutteman
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 5.  Hormones and breast and endometrial cancers: preventive strategies and future research.

Authors:  B S Hulka; L A Brinton
Journal:  Environ Health Perspect       Date:  1995-11       Impact factor: 9.031

6.  Does oral contraceptive pill increase the risk of abnormal Pap smear?

Authors:  Fariba Binesh; Ali Akhavan; Azar Pirdehghan; Mahnoosh Davoodi
Journal:  Iran J Reprod Med       Date:  2013-09

7.  Risk factors associated with precancerous cervical lesion among women screened at Marie Stops Ethiopia, Adama town, Ethiopia 2017: a case control study.

Authors:  Roza Teshome Kassa
Journal:  BMC Res Notes       Date:  2018-02-20

8.  MDM2 polymorphism associated with the development of cervical lesions in women infected with Human papillomavirus and using of oral contraceptives.

Authors:  Carolina Mm Amaral; Katerina Cetkovská; Ana Pad Gurgel; Marcus V Cardoso; Bárbara S Chagas; Sérgio Sl Paiva Júnior; Rita de Cássia Pereira de Lima; Jacinto C Silva-Neto; Luiz Af Silva; Maria Tc Muniz; Valdir Q Balbino; Antonio C Freitas
Journal:  Infect Agent Cancer       Date:  2014-07-18       Impact factor: 2.965

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.